Ebola Vaccines Clinical Trial
Official title:
A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
| Verified date | January 2016 |
| Source | Centre Hospitalier Universitaire Vaudois |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Switzerland: Swissmedic |
| Study type | Interventional |
The objective of this trial is to assess in healthy adults the safety and reactogenicity of a new candidate vaccine, cAd3-EBOZ, made of a chimpanzee Adenovirus vector encoding the glycoprotein of Zaire Ebola virus. The secondary objectives will be to assess the immunogenicity of the candidate vaccine and find the most suitable dose for further deployment in epidemic areas in Africa. The 120 planned study subjects will be composed of possibly exposed volunteers owning to organisations such as "Médecins sans frontières" and susceptible to be deployed in the outbreak zone (named as "possibly exposed volunteers"). The other volunteers will be adults with no planned travels to the epidemic zone (named as "not exposed volunteers"). The first group will be randomly allocated to two different groups (low dose = single injection of 2.5x10e10 viral particles (vp), high dose = single injection of 5x10e10 vp). The second group will be randomly allocated to three different groups (low dose = single injection of 2.5x10e10 viral particles (vp), high dose = single injection of 5x10e10 vp or placebo = single injection of vaccine diluent). The design will be double-blind. Follow-up visits will take place at Day 1, 7, 14, 28, 90 and 180.
| Status | Completed |
| Enrollment | 120 |
| Est. completion date | June 2015 |
| Est. primary completion date | June 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: 1. Healthy adults aged 18 to 65 years 2. Able and willing (in the Investigator's opinion) to comply with all study requirements 3. Willing to allow the investigators to discuss the volunteer's medical history with their general practitioner 4. For females of reproductive capacity and males, having practiced continuous effective contraception for 21 days prior to enrolment, and willing to practice continuous effective contraception for 3 months post vaccination 5. For females of reproductive capacity, having a negative pregnancy test on the day(s) of screening and vaccination if >7 days interval 6. Agreement to refrain from blood donation during the course of the study 7. Provide written informed consent Exclusion Criteria: 1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period 2. Prior receipt of an investigational Ebola or Marburg vaccine or a chimpanzee adenovirus vectored vaccine 3. Receipt of any live, attenuated vaccine within 28 days prior to enrolment 4. Receipt of any subunit or killed vaccine within 14 days prior to enrolment (influenza vaccination is encouraged prior to participation) 5. Receipt of any investigational vaccine within 3 months prior to enrollment 6. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate 7. Any confirmed or suspected immunosuppressed or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressive medication within the past 6 months (inhaled and topical steroids are allowed) 8. History of allergic reactions likely to be exacerbated by any component of the vaccine, 9. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema. 10. Any history of anaphylaxis in reaction to vaccination 11. Pregnancy, lactation or willingness/intention to become pregnant during the study 12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) 13. History of serious psychiatric condition 14. Poorly controlled asthma or thyroid disease 15. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years 16. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture 17. Any other serious chronic illness requiring hospital specialist supervision 18. Current anti-tuberculosis prophylaxis or therapy 19. Suspected or known current alcohol abuse 20. Suspected or known injecting drug abuse in the 5 years preceding enrolment 21. Seropositive for hepatitis B surface antigen (HBsAg) 22. Seropositive for hepatitis C virus (antibodies to HCV) 23. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis 24. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Switzerland | Clinical Trial Unit Lausanne | Lausanne |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire Vaudois | Clinical Trial Unit, Lausanne University Hospital, GlaxoSmithKline, Immunology and Allergy Service, CHUV, Lausanne, Infectious Disease Service, CHUV, Lausanne, Policlinique Médicale Universitaire, Swiss Tropical & Public Health Institute, University of Lausanne, World Health Organization |
Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | T cell immune responses as measured by intracellular cytokine staining assays (ICS) | Through 6 months after the vaccination | No | |
| Other | T cell immune responses as measured by 6-day culture cytokine production by Multiplex and flow cytometry | Through 6 months after the vaccination | No | |
| Other | HLA typing | On Day 0 (day of vaccination) | No | |
| Other | Vaccine-induced mRNA expression profiles (transcriptomics) | Through 28 days after the vaccination | No | |
| Primary | Solicited local and systemic reactogenicity signs and symptoms | Solicited local signs and symptoms include: pain at injection site; erythema at injection site; swelling at injection site. They will be assessed according to a preestablished scale (grade 1 to 3). Solicited systemic signs and symptoms include: fever; tachycardia; bradycardia; systolic hypertension; distolic hypertension; systolic hypotension. They will be assessed according to a preestablished scale (grade 1 to 3). |
Daily for 7 days following the vaccination | Yes |
| Primary | Unsolicited adverse events of all severities | Unsolicited adverse events will be assessed according to a severity grading scale (grade 1 to 3). | Through 28 days after the vaccination | Yes |
| Primary | Change from baseline for safety laboratory measures | Safety laboratory measures include: hemoglobin; white blood cells count; neutrophil count; lymphocyte count; platelets; total bilirubin; alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase; creatinine; urea; sodium; potassium; partial thromboplastin time (aPTT). They will be assessed according to a severity grading scale (grade 1 to 3). | Through 6 months after the vaccination | Yes |
| Primary | Occurrence of serious adverse events and suspected unexpected serious adverse reactions | SAE are defined as AE that result in any of the following outcomes, whether or not considered related to the study intervention: Death Life-threatening event Persistent or significant disability or incapacity Hospitalisation An important medical event (that may not cause death, be life threatening, or require hospitalisation) that may, based upon appropriate medical judgment, jeopardise the volunteer and/or require medical or surgical intervention to prevent one of the outcomes listed above. Congenital anomaly or birth defect. A SUSAR is a suspected unexpected serious adverse reaction thought to be possibly, probably or definitely related to an IMP. No category of SAE has been defined as 'expected'. |
Through 6 months after the vaccination | Yes |
| Secondary | Antibody responses as measured by ELISA (anti-EBOZ immunoglobulins titers) and by antigen-specific neutralization assays | Through 6 months after the vaccination | No | |
| Secondary | T cell immune responses as measured by ex-vivo ELISPOT | Through 6 months after the vaccination | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00605514 -
Ebola and Marburg Virus Vaccines
|
Phase 1 |